What Apasmo Treats: Main Uses and Benefits

Apasmo is commonly used to help manage distressing symptoms across several functional areas. Its primary benefit is providing symptomatic support that may improve patient comfort during disruptive episodes. It may be used to help address symptoms associated with functional gastrointestinal disorders, irritable bowel syndrome (IBS), and certain bladder-related issues.

---

Easing Sudden Symptomatic Discomfort

This medication is generally used to relieve physical discomfort that may appear suddenly or intensify temporarily. It provides support that helps ease the overall symptom burden in settings where short-term symptom management is appropriate.

Quick Fact: Often used for symptomatic support for sudden cramping and tension.

---

Management of Functional Strain and Symptoms

Apasmo is relevant in contexts marked by increased discomfort or tension, particularly those associated with symptoms related to heightened physiological activity. It is applied when these symptom clusters create noticeable functional strain, assisting with maintaining functional stability during symptomatic periods.

“The approach focuses on relieving functional symptoms of discomfort and tension, which may support improved patient comfort.”

---

Support for Episodic and Fluctuating Conditions

The treatment is commonly used across conditions characterized by periods of heightened symptoms or recurrent manifestations. It offers symptomatic relief that may help patients cope more steadily when symptoms escalate temporarily, supporting general well-being during difficult, episodic changes.

Regulatory References

1. NIH National Library of Medicine overview

Eligibility and Contraindications for Apasmo

Apasmo (apomorphine) is not appropriate for all patients. Official regulatory documents define specific populations who must not use this medicine, as well as groups who require special caution and monitoring.

Classification	Population/Condition
Contraindicated	Known hypersensitivity to apomorphine, sodium metabisulfite, or any component in the product.
Contraindicated	Concomitant use with 5HT3 antagonists (such as ondansetron, granisetron, palonosetron, and alosetron) due to the risk of profound hypotension and loss of consciousness.
Contraindicated	Patients with severe hepatic insufficiency or severe active liver disease.
Contraindicated	Patients with pre-existing severe neuropsychiatric problems or dementia, or those with a poor 'on' response to levodopa marred by severe dyskinesia or psychotoxicity.
Use Restricted	Children and adolescents under 18 (safety and efficacy are not established).
Use Restricted	Patients with a history of hypotension or conditions predisposing to QTc prolongation (heart rhythm issues).
Special Consideration	Pregnancy and Lactation (use is generally not recommended due to insufficient safety data or potential for fetal harm shown in animal studies).

Healthcare providers must carefully assess patient eligibility, particularly regarding liver function and the use of concomitant medications known to interact, to ensure safe administration.

A drug interaction is a change in the way a medicine acts in the body when taken with certain other medicines, foods, or supplements. The official regulatory profile for Apasmo structures interactions into distinct categories based on their nature and clinical implications, ensuring all known risks are communicated.

Interaction Classification

Interaction Type	Description (Regulatory Focus)
Exposure Alteration (PK)	Interactions that significantly change the concentration of Apasmo or a co-administered drug in the body, often through effects on the CYP enzyme system or drug transporters (e.g., P-gp).
Pharmacodynamic Overlap (PD)	Interactions where Apasmo is combined with substances having a similar physiological effect, leading to a potentially increased, additive, or synergistic response.

Official Interaction Statements

Official labeling requires specific statements for medicinal products, herbal supplements, and food or alcohol that are known to affect the drug's safety or effectiveness.

• Medicines: Certain drug classes are identified as requiring precautionary co-administration, such as those that inhibit or induce drug-metabolizing enzymes, potentially leading to increased or decreased Apasmo exposure, respectively.
• Food/Beverages: Specific instructions may be issued regarding administration with or without food, or the need to avoid alcohol or particular food components due to documented effects on drug absorption or risk of side effects.
• Herbal Supplements: The use of specific herbal products, such as St. John's Wort, which can significantly alter drug metabolism, is officially discouraged or requires heightened monitoring due to their potential to reduce drug exposure.

These mandated classifications define the conditions under which Apasmo may or may not be safely combined with other products, thereby establishing the necessary constraints for use.

Dual-Action Control of Visceral Smooth Muscle

Apasmo’s antispasmodic mechanism acts via a dual-action strategy on the muscle tissue. It engages the muscarinic acetylcholine receptor ( M3) antagonism and simultaneously inhibits the enzyme Phosphodiesterase type IV ( PDE-IV). This dual molecular cascade reduces the level of free intracellular calcium ions ( Ca^2+) required for contraction, leading to the inhibition of smooth muscle contraction.

---

Multi-Target Central and Peripheral Analgesia

The analgesic component acts via a multi-target mechanism that primarily affects central nociceptive pathways. It involves the inhibition of the central enzyme Cyclooxygenase-3 ( COX-3), antagonism of the nociceptive TRPA1 ion channel, and modulation of the descending pain pathways via the central CB1 receptor. This array of molecular interactions modulates the central transmission of nociceptive signals by inhibiting impulse propagation at the spinal and supraspinal levels.

---

Coordinated Modulation of the Spasm-Nociception Axis

The drug's overall physiological effect results from the coordinated action of its components. Spasmolysis structurally inhibits the involuntary muscle contraction, while Analgesia simultaneously modulates the associated nociceptive signaling. This coordinated intervention facilitates the simultaneous modulation of muscle tone and nociceptive transmission.

Administration Guidelines

Apasmo, a fixed-dose combination containing Sodium Metamizole and Camylofin, is used for short-term, acute symptomatic relief following established parameters for administration, dosage, and frequency.

Approved Routes and Forms

There are two primary administration routes:

• Oral: For the Tablet form, used in general outpatient settings.
• Parenteral: For the Injectable Solution, administered via Intramuscular (IM) or Intravenous (IV) injection in a supervised setting for acute episodes.

Standard Dosing and Frequency

Treatment is typically initiated with the lowest effective dose. The following limits apply for the Metamizole component for adults (ge 15 years):

Dosing Instruction	Limit/Requirement
Single Oral Dose	Up to 1,000 mg
Maximum Oral Daily Dose	4,000 mg
Dose Interval	A minimum of 6 to 8 hours between doses

Administration Conditions

• Oral Intake: Tablets may be taken with or without food.
• IV Injection: When administered intravenously, the drug is delivered as a slow injection or infusion by a qualified professional.

Population-Specific Use

Caution is required for certain groups:

• Older Adults & Impairment: Patients with renal or hepatic impairment or those who are older typically use the lowest dose; dose reduction is generally required.
• Pediatric Patients: Dosing is weight-based. Fixed-dose tablets are often not recommended for the youngest patients due to challenges in achieving accurate weight-based dosing.

Research evidence / Overview of studies for Apasmo

---

Evidence for Use in Acute Visceral Pain and Colic

Research exploring the combination of an analgesic and an antispasmodic, such as Apasmo (Camylofin/Metamizole), was studied for its relevance in periods of heightened symptom activity associated with sudden, severe cramping pain, known as colic. This research primarily relies on short-term Randomized Controlled Trials (RCTs) and systematic reviews conducted in settings where quick assessment is utilized. The studies research examined outcomes related to physical discomfort, primarily measuring the degree of symptom intensity or variability using standardized pain scales over brief intervals.

Studies report how symptoms evolved in the observed populations during the first few hours or days of an acute episode. Findings describe patterns observed in the studies related to the time needed to achieve the measured level of change in patient-reported outcomes describing perceived discomfort. The evidence for this acute setting is predominantly short-term, meaning the studies provide limited insight into outcomes once the initial acute phase passes.

---

Evidence for Postoperative and Other Acute Pain

Research was studied for its relevance in settings involving other forms of acute pain, such as that experienced after surgical procedures. The evidence base here largely consists of RCTs and meta-analyses that research examined the component acting as an analgesic compared to other treatments. These studies explored outcomes describing episodic or acute changes in pain scores and the need for supplemental pain medication.

Specific research dedicated to the Camylofin/Metamizole combination for postoperative pain is less frequent than evidence for the component acting as an analgesic alone. Therefore, the evidence quality varies across studies, and the specific contribution of the spasmolytic component is not always the primary focus in the most extensive trials. The results apply only to the populations studied, which were typically general adult surgical patients.

---

Research Gaps and Areas of Uncertainty

The research on Apasmo contributes to the broader evidence landscape for spasm-related pain, but several areas of uncertainty have been noted. Data for certain groups remain insufficient; research provides limited context for use in pediatric, older adult, or pregnant populations. Furthermore, comparative evidence is lacking for certain indications, making it difficult to fully contextualize the observed patterns against all other available treatment options. Limited information for long-term outcomes means the research does not determine whether an individual's long-term symptom management will be affected by its use.

Key Studies & References

1. Gastrointestinal Agents Drug Class Overview

Common questions about Apasmo (FAQ)

---

Q: What is the recommended storage temperature for Apasmo tablets?

Official administration guidelines state that Apasmo should be stored at Controlled Room Temperature, typically below 25°C or 30°C. It must be kept in the original container to protect it from light and moisture, and freezing the product should be avoided.

---

Q: Is Apasmo a non-steroidal anti-inflammatory drug (NSAID)?

Apasmo is classified as a combination product containing a non-opioid analgesic and an antispasmodic. The analgesic component, Metamizole, is classified as a pyrazolone derivative and a non-opioid analgesic, which is a class different from traditional NSAIDs.

---

Q: Is there a maximum number of days I should take Apasmo?

Regulatory documents indicate that Apasmo is intended for short-term, acute symptomatic relief of pain. While specific limits on the duration of use may vary, treatment should be limited to the shortest possible period for an acute episode. Consultation with a healthcare professional is generally required if symptoms persist beyond the acute phase.

---

Q: What types of pain is Apasmo typically used for?

Official indications state use for acute pain associated with smooth muscle spasm, such as that occurring in episodes of colic. Apasmo is designed to provide symptomatic relief from acute pain linked to involuntary muscular contractions.

---

Q: How long does Apasmo stay in your system?

Product information on pharmacokinetics indicates that the active metabolite of the analgesic component has an elimination half-life of approximately 2 to 6 hours. This indicates the time frame over which the substance is typically cleared from the body.

---

Q: What are the common signs of an allergic reaction to Apasmo?

Official warnings note that serious hypersensitivity reactions, like Anaphylactic Shock, are possible. Signs of an allergic reaction may include symptoms such as hives (urticaria), swelling of the face, lips, or throat, or difficulty breathing. If signs of a hypersensitivity reaction are observed, it is important to contact a healthcare provider immediately.

---

Q: Can I drink alcohol while taking Apasmo?

Official labeling advises patients to avoid alcohol consumption while using Apasmo. Combining the two can increase the risk of certain side effects, particularly those affecting the central nervous system (e.g., drowsiness) or the liver.

How to Store and Dispose of Apasmo?

The official storage and disposal guidelines ensure the medicine remains stable and is discarded safely, according to regulatory standards for Fixed-Dose Combinations containing Camylofin and Metamizole.

---

Storage Requirements

• Temperature: Store the product at Controlled Room Temperature, typically below 25°C or 30°C.
• Protection: Keep the medicine in its original container or carton to protect it from light and moisture.
• Handling: Do not freeze the product. Keep the container tightly closed where applicable.
• Child Safety: All medication must be stored securely out of the sight and reach of children and pets.

---

Disposal Instructions

• Unused or expired Apasmo must be disposed of in accordance with local regulatory requirements.
• The product should not be disposed of by throwing it in household waste or flushing it down a toilet.